Burnand B, Kernan WN, Feinstein AR Indexes and boundaries for "quantitative significance" in statistical decisions. J Clin Epidemiol. 1990;43(12):1273-84.
Charlson ME, Pompei P, Ales KL, MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
Corrigan JM, Martin JB Identification of factors associated with hospital readmission and development of a predictive model. Health Serv Res. 1992 Apr;27(1):81-101.
Deyo RA, Cherkin DC, Ciol MA Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613-9.
Donner A, Birkett N, Buck C Randomization by cluster. Sample size requirements and analysis. Am J Epidemiol. 1981 Dec;114(6):906-14.
Donner A, Donald A Analysis of data arising from a stratified design with the cluster as unit of randomization. Stat Med. 1987 Jan-Feb;6(1):43-52.
Donner A, Klar N Pitfalls of and controversies in cluster randomization trials. Am J Public Health. 2004 Mar;94(3):416-22.
Grimmer K, Moss J The development, validity and application of a new instrument to assess the quality of discharge planning activities from the community perspective. Int J Qual Health Care. 2001 Apr;13(2):109-16.
Hauck WW, Anderson S, Marcus SM Should we adjust for covariates in nonlinear regression analyses of randomized trials? Control Clin Trials. 1998 Jun;19(3):249-56. Review.
Hedeker D, Gibbons RD MIXOR: a computer program for mixed-effects ordinal regression analysis. Comput Methods Programs Biomed. 1996 Mar;49(2):157-76.
Hedeker D, Gibbons RD MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors. Comput Methods Programs Biomed. 1996 May;49(3):229-52.
Hedeker D, Siddiqui O, Hu FB Random-effects regression analysis of correlated grouped-time survival data. Stat Methods Med Res. 2000 Apr;9(2):161-79.
Heitjan DF Annotation: what can be done about missing data? Approaches to imputation. Am J Public Health. 1997 Apr;87(4):548-50.
Horne R, Hankins M, Jenkins R The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001 Sep;10(3):135-40.
Hsieh FY Sample size formulae for intervention studies with the cluster as unit of randomization. Stat Med. 1988 Nov;7(11):1195-201. Erratum in: Stat Med 1997 Jun 15;16(11):1300.
Hunsberger S, Murray D, Davis CE, Fabsitz RR Imputation strategies for missing data in a school-based multi-centre study: the Pathways study. Stat Med. 2001 Jan 30;20(2):305-16.
Johnson A, Sandford J, Tyndall J Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home. Cochrane Database Syst Rev. 2003;(4):CD003716. Review.
Kerry SM, Bland JM Unequal cluster sizes for trials in English and Welsh general practice: implications for sample size calculations. Stat Med. 2001 Feb 15;20(3):377-90.
Manos PJ, Wu R The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. Int J Psychiatry Med. 1994;24(3):229-44.
McInnes E, Mira M, Atkin N, Kennedy P, Cullen J Can GP input into discharge planning result in better outcomes for the frail aged: results from a randomized controlled trial. Fam Pract. 1999 Jun;16(3):289-93.
Murray DM, Varnell SP, Blitstein JL Design and analysis of group-randomized trials: a review of recent methodological developments. Am J Public Health. 2004 Mar;94(3):423-32. Review.
Nace GS, Graumlich JF, Aldag JC Software design to facilitate information transfer at hospital discharge. Inform Prim Care. 2006;14(2):109-19.
Novotny NL, Anderson MA Prediction of early readmission in medical inpatients using the Probability of Repeated Admission instrument. Nurs Res. 2008 Nov-Dec;57(6):406-15. doi: 10.1097/NNR.0b013e31818c3e06.
Pacala JT, Boult C, Boult L Predictive validity of a questionnaire that identifies older persons at risk for hospital admission. J Am Geriatr Soc. 1995 Apr;43(4):374-7.
Pacala JT, Boult C, Reed RL, Aliberti E Predictive validity of the Pra instrument among older recipients of managed care. J Am Geriatr Soc. 1997 May;45(5):614-7.
Romano PS, Chan BK Risk-adjusting acute myocardial infarction mortality: are APR-DRGs the right tool? Health Serv Res. 2000 Mar;34(7):1469-89.
Sands DZ, Safran C Closing the loop of patient care--a clinical trial of a computerized discharge medication program. Proc Annu Symp Comput Appl Med Care. 1994:841-5.
Shelton P, Sager MA, Schraeder C The community assessment risk screen (CARS): identifying elderly persons at risk for hospitalization or emergency department visit. Am J Manag Care. 2000 Aug;6(8):925-33.
Shepperd S, Parkes J, McClaren J, Phillips C Discharge planning from hospital to home. Cochrane Database Syst Rev. 2004;(1):CD000313. Review. Update in: Cochrane Database Syst Rev. 2010;(1):CD000313.
van Walraven C, Seth R, Austin PC, Laupacis A Effect of discharge summary availability during post-discharge visits on hospital readmission. J Gen Intern Med. 2002 Mar;17(3):186-92.
van Walraven C, Seth R, Laupacis A Dissemination of discharge summaries. Not reaching follow-up physicians. Can Fam Physician. 2002 Apr;48:737-42.
Weinberger M, Oddone EZ, Henderson WG Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med. 1996 May 30;334(22):1441-7.
Value of Technology to Transfer Discharge Information
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.